AARTI DRUGS LTD. - 524348 - Investor Presentation
Please find enclosed herewith FY20 Results Presentation of the Company for your records.23-06-2020
23-06-2020
AARTI DRUGS LTD. - 524348 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Rajendra Vallabhaji Gogri & Others19-06-2020
DGTR recommends anti-dumping duty on import of Ciprofloxacin HCL
The DGTR move comes after a complaint by Aarti Drugs16-06-2020
AARTI DRUGS LTD. - 524348 - Compliance Under Regulation 23(9) Of SEBI (LODR) Regulations, 2015
In compliance with Regulation 23(9) of SEBI (LODR) Regulations, 2015 we enclose disclosure of Related Party Transactions on a consolidated basis for the half year ended March 31, 2020.09-06-2020
Buy Aarti Drugs; target of Rs 1028: Anand Rathi
Anand Rathi is bullish on Aarti Drugs has recommended buy rating on the stock with a target price of Rs 1028 in its research report dated May 19, 2020.20-05-2020
AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find attached herewith press release on the financial results for the quarter and year ended March 31, 2020.18-05-2020
Earnings Call Transcript - Q4FY20 for Aarti Drugs
Conference Call with Aarti Drugs Management and Analysts on Q4FY20 and Full Year Earnings Performance and Outlook. Listen in to the full earnings transcript.18-05-2020
AARTI DRUGS LTD. - 524348 - Outcome Of The Board Meeting - Appointment Of Director
The Board of Directors in its meeting held on May 15, 2020 has proposed the appointment of Shri Narendra Jagannath Salvi (DIN: 00299202) as Non-executive Director of the Company in the ensuing Annual General Meeting for the approval of the shareholders.16-05-2020
AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
This is to inform you that Quarterly Conference Call for the Investors and Analysts has been scheduled on Monday, May 18, 2020 at 3:00 PM IST to discuss the Company's Q4 FY20 Results. Please find attached herewith invitation for the same.15-05-2020